Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial

I Ismail Gögenur (Center for Surgical Science, Zealand University Hospital, Køge, Denmark) T Tobias F. Justesen (Center for Surgical Science, Zealand University Hospital, Køge, Denmark) L Line S. Tarpgaard (Department of Oncology, Odense University Hospital, Odense, Denmark) M Mustafa Bulut T Torben F. Hansen L Lars H. Jensen (Department of Oncology, Vejle Hospital, Vejle, Denmark) H Hans B. Rahr (Department of Surgery, Colorectal Cancer Center South at Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark) M Mikail Gögenur (Center for Surgical Science, Zealand University Hospital, Køge, Denmark) T Tove Kirkegaard (Center for Surgical Science, Zealand University Hospital, Køge, Denmark) L Lukas Balsevicius (Center for Surgical Science, Zealand University Hospital, Køge, Denmark) M Michael Chieng (Center for Surgical Science, Zealand University Hospital, Køge, Denmark) H Hans Raskov (Center for Surgical Science, Zealand University Hospital, Køge, Denmark) M Mia K.S. Sørensen (Center for Surgical Science, Zealand University Hospital, Køge, Denmark) P Peter C. Petersen (Department of Oncology, Zealand University Hospital, Roskilde, Denmark) J Jens R. Eriksen (Department of Surgery, Zealand University Hospital, Køge, Denmark) S Søren Salomon (Department of Surgery, Odense University Hospital, Odense, Denmark) A Anne-Marie K. Fiehn (Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark) M Maria Dalgaard Mikkelsen (Department of Pathology, Zealand University Hospital, Roskilde, Denmark) S Søren Brandsborg (Department of Surgery, Horsens Regional Hospital, Horsens, Denmark) K Kåre A. Gotschalck (Department of Surgery, Horsens Regional Hospital, Horsens, Denmark) K Katrine J. Emmertsen (Department of Surgery, Randers Regional Hospital, Randers, Denmark) A Anne Ramlov (Department of Oncology, Aarhus University Hospital, Aarhus, Denmark) P Pernille W. Born (Department of Surgery, Hvidovre Hospital, Hvidovre, Denmark) O Ole Thorlacius-Ussing (Department of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark) M Michael B. Lauritzen (Department of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark) R René K. Olesen (Department of Oncology, Aalborg University Hospital, Aalborg, Denmark) L Laurids Ø. Poulsen (Department of Oncology, Aalborg University Hospital, Aalborg, Denmark) J Jakob Lykke (Department of Surgery, Herlev and Gentofte University Hospital, Herlev, Denmark) J Jakob Schou (Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark) L Laura Buskov (Department of Radiology, Bispebjerg Hospital, Bispebjerg, Denmark) P Peter-Martin Krarup C Claus L. Andersen (Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark) N Niels Pallisgaard (Department of Pathology, Zealand University Hospital, Roskilde, Denmark) P Per Pfeiffer (Department of Oncology, Odense University Hospital, Odense, Denmark) C Camilla Qvortrup (Department of Oncology, Rigshospitalet, Copenhagen, Denmark)

Abstract

PURPOSE Neoadjuvant immune checkpoint inhibition has shown promise in localized deficient mismatch repair (dMMR) colorectal cancer, yet the optimal treatment duration, regimen, and methods for response evaluation remain undefined. This trial aimed to investigate the efficacy and safety of neoadjuvant pembrolizumab for patients with localized dMMR colon cancer. METHODS Participants received a single cycle of pembrolizumab (4 mg/kg, max 400 mg, every-6-weeks dosing regimen), followed by a preoperative endoscopy with biopsies and surgery 3-5 weeks later. The primary end point was pathologic complete response (pCR); secondary and exploratory end points included major pathologic response (MPR), safety, survival, and endoscopic response assessment. RESULTS From February 2023 to March 2024, 85 patients (median age 74 years) were enrolled. All received pembrolizumab; one patient declined surgery. Among 84 patients, pCR was achieved in 44% (37 of 84; 95% CI, 33 to 55), and MPR in 57% (48 of 84; 95% CI, 46 to 68). Two (2%) patients died of complications within 30 days of surgery. At a median follow-up of 18.4 months (IQR, 16.3-21.1), one patient had a recurrence, resulting in overall and disease-free survival rates of 98% and 96%. Grade 3 adverse events occurred in 11% of patients (9 of 85; 95% CI, 3 to 16), with three treatment-related events. In 81 patients, the sensitivity, specificity, and accuracy of the biopsies for predicting pCR were 68%, 75%, and 72%, respectively. In 76 patients, the sensitivity, specificity, and accuracy of the endoscopic images for predicting pCR were 77%, 93%, and 86%, respectively. CONCLUSION A single cycle of neoadjuvant pembrolizumab led to pCR in nearly half of patients undergoing surgery for localized dMMR colon cancer. The utility of endoscopic evaluation may inform future strategies for patient selection in nonoperative management pathways.

Article Details

Volume / Issue Vol. 44, Issue 18
Published June 20, 2026
Pages 1687-1696
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (35)

I

Ismail Gögenur

Center for Surgical Science, Zealand University Hospital, Køge, Denmark

T

Tobias F. Justesen

Center for Surgical Science, Zealand University Hospital, Køge, Denmark

L

Line S. Tarpgaard

Department of Oncology, Odense University Hospital, Odense, Denmark

M

Mustafa Bulut

T

Torben F. Hansen

L

Lars H. Jensen

Department of Oncology, Vejle Hospital, Vejle, Denmark

H

Hans B. Rahr

Department of Surgery, Colorectal Cancer Center South at Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark

M

Mikail Gögenur

Center for Surgical Science, Zealand University Hospital, Køge, Denmark

T

Tove Kirkegaard

Center for Surgical Science, Zealand University Hospital, Køge, Denmark

L

Lukas Balsevicius

Center for Surgical Science, Zealand University Hospital, Køge, Denmark

M

Michael Chieng

Center for Surgical Science, Zealand University Hospital, Køge, Denmark

H

Hans Raskov

Center for Surgical Science, Zealand University Hospital, Køge, Denmark

M

Mia K.S. Sørensen

Center for Surgical Science, Zealand University Hospital, Køge, Denmark

P

Peter C. Petersen

Department of Oncology, Zealand University Hospital, Roskilde, Denmark

J

Jens R. Eriksen

Department of Surgery, Zealand University Hospital, Køge, Denmark

S

Søren Salomon

Department of Surgery, Odense University Hospital, Odense, Denmark

A

Anne-Marie K. Fiehn

Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

M

Maria Dalgaard Mikkelsen

Department of Pathology, Zealand University Hospital, Roskilde, Denmark

S

Søren Brandsborg

Department of Surgery, Horsens Regional Hospital, Horsens, Denmark

K

Kåre A. Gotschalck

Department of Surgery, Horsens Regional Hospital, Horsens, Denmark

K

Katrine J. Emmertsen

Department of Surgery, Randers Regional Hospital, Randers, Denmark

A

Anne Ramlov

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

P

Pernille W. Born

Department of Surgery, Hvidovre Hospital, Hvidovre, Denmark

O

Ole Thorlacius-Ussing

Department of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark

M

Michael B. Lauritzen

Department of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark

R

René K. Olesen

Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

L

Laurids Ø. Poulsen

Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

J

Jakob Lykke

Department of Surgery, Herlev and Gentofte University Hospital, Herlev, Denmark

J

Jakob Schou

Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark

L

Laura Buskov

Department of Radiology, Bispebjerg Hospital, Bispebjerg, Denmark

P

Peter-Martin Krarup

C

Claus L. Andersen

Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark

N

Niels Pallisgaard

Department of Pathology, Zealand University Hospital, Roskilde, Denmark

P

Per Pfeiffer

Department of Oncology, Odense University Hospital, Odense, Denmark

C

Camilla Qvortrup

Department of Oncology, Rigshospitalet, Copenhagen, Denmark